Compare Merck & Co., Inc. (MRK) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Star Bulk Carriers Corp — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Star Bulk Carriers Corp trades at $26.59 (market cap $2.91B). The key difference: Merck & Co., Inc. is far larger — about 105.6× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (3.95%). Which is the better fit depends on your goals.
| MRK | SBLK | |
|---|---|---|
Market Cap | $307.25B | $2.91B |
Sector | Health | Industrials |
52-Week High | $129.52 | $28.21 |
52-Week Low | $77.60 | $16.79 |
Enterprise Value | $350.66B | $3.61B |
Dividend Yield | 2.73% | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. Financials show improving profitability, with a net income margin of 13.01% in 2026, and a dividend of $0.50 paid in June 2026. Analyst consensus is bullish, with 14 buys out of 24 ratings.
SBLK's outlook is supported by robust free cash flow and a healthier balance sheet, but risks include spot rate volatility and broader market pressures. The stock offers potential for high dividend yields and earnings growth, though investor caution is warranted amid sector cyclicality and economic uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
